Please login to the form below

Not currently logged in
Email:
Password:

ViiV Healthcare

This page shows the latest ViiV Healthcare news and features for those working in and with pharma, biotech and healthcare.

GSK preps COPD filing for asthma pioneer Nucala

GSK preps COPD filing for asthma pioneer Nucala

at least outside of its buoyant HIV unit ViiV Healthcare - and needs to squeeze every drop of potential out of its new products while it tries to build up its

Latest news

  • ViiV files two-drug HIV maintenance regimen ViiV files two-drug HIV maintenance regimen

    ViiV files two-drug HIV maintenance regimen. SWORD studies show treatment could maintain viral suppression. ... ViiV Healthcare has filed its first marketing application for a two-drug regimen that could simplify antiretroviral maintenance therapy for HIV

  • Power to the people Power to the people

    they’re also engaged in their disease understanding and in the healthcare system that supports them. ... However, happily, brands and businesses are growing up. There are some really innovative companies, such as ViiV Healthcare and some of the larger

  • Gilead plans fightback against HIV arch-rival ViiV Gilead plans fightback against HIV arch-rival ViiV

    Gilead plans fightback against HIV arch-rival ViiV. Descovy sees phase III success after the TAF-based drug proves non-inferior to Triumeq. ... The fixed dose combination of integrase strand inhibitor bictegravir with the two active ingredients in

  • Walmsley suggests GSK needs bigger product launches Walmsley suggests GSK needs bigger product launches

    the company's majority-owned ViiV Healthcare unit, with regulatory decisions on all of these expected in the next 12 months, said Walmsley.

  • Pharma's reputation on the wane, say patient groups Pharma's reputation on the wane, say patient groups

    PatientView's survey also looks at individual pharma companies' reputations and this year's poll revealed that ViiV Healthcare - the HIV-focused joint venture between GlaxoSmithKline (GSK), Pfizer and Shionogi - was ... ViiV led the pack overall and

More from news
Approximately 15 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    The first is the revised deal between ViiV Healthcare (the speciality HIV company formed by GSK and Pfizer in 2009) and Shionogi. ... Under the new agreement, ViiV Healthcare will acquire the exclusive global rights to the assets in the Shionogi-ViiV

  • Shionogi: an expanding commercial focus Shionogi: an expanding commercial focus

    The candidate the company is most excited about is the nce-daily HIV integrase inhibitor dolutegravir, which Shionogi is co-developing with the Pfizer and GlaxoSmithKline's ViiV Healthcare venture. ... Establishes Shionogi-GlaxoSmithKline joint venture

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet

    GlaxoSmithKline has promoted Deborah Waterhouse to replace ViiV Healthcare's CEO Dominique Limet when he steps down from the HIV-focused firm at the end of March. ... He said: “ Establishing and then leading ViiV Healthcare for the past seven years has

  • Phil Golz appointed commercial director at HealthUnlocked Phil Golz appointed commercial director at HealthUnlocked

    Phil Golz appointed commercial director at HealthUnlocked. Moves from ViiV Healthcare to join the socialnetwork for health. ... He joins the company from ViiV Healthcare, where he was executive director, and prior to that he served as head of commercial

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Munro & Forster

At Munro & Forster we deliver real and lasting impact for our clients.We specialise in health and wellbeing, education and...

Latest intelligence

Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...
So how do you really engage with patients?
The most valuable insights from patient engagement are the most unexpected ones. Simple things, which may seem unimportant to you, may be the key to making patients’ lives easier and...
data
Avoiding data pitfalls in clinical research
Genomics sequencing and sensors will present new challenges...

Infographics